Equibles does not estimate personal net worth.
Get an email with a short summary when Gilead Sciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get GILD alertsCindy Perettie has spoken on 6 earnings calls and 1 other investor event across 1 company, most recently for Gilead Sciences, Inc. on November 10, 2026. Gilead Sciences, Inc. is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Gilead Sciences, Inc. includes Daniel P. O’Day (CEO), Robin L. Washington (CFO), Diane E. Wilfong (Chief Accounting Officer) and 7 others.
“You know, the piece that Yskarta and Takardis have allowed us to do is set the foundation, and cell therapy is not a typical delivery model, so you need to build up a number of aspects.”
“If you look at both our IMAGINE-3 trial as well as our newly diagnosed trials, they are co-primary I'm going to talk to you about primary endpoints, looking at MRD, followed by PFS.”
“So, with AnitaCell, we haven't communicated what our filing dates are, nor will we, but what we have communicated is that we're very much looking forward to a launch second half of next year, and we're definitely on track for that.”
“So just how you get comfortable with the feedback from years past still applies, and if there's ongoing feedback that bolsters that confidence thank you yeah i know we we're not communicating our regulatory strategy other than to say that we are continuing to have conversations with the fda and are looking forward to…”
“So our goal is to use the MRD negativity endpoint first, and then follow that up with progression-free survival, but the correlation between the two is what we're talking to regulators about.”
Source not stated
Drug Manufacturers - General · Healthcare
